14.11.2023 - LONDON and SALT LAKE CITY, Nov. 14, 2023 (GLOBE NEWSWIRE) - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved .
Diagnostic artificial intelligence (AI) specialist Renalytix announced an enhancement to its intellectual property portfolio for its KidneyIntelX.dkd test on Friday.
ANN/THE STAR – Those with type 2 diabetes who are planning out their exercise schedule should consider getting in a workout after lunch, according to a new study from American researchers. Type 2 diabetes patients who were physically active in the afternoon saw greater improvements in blood sugar levels than those who were most active […]